SEARCH

SEARCH BY CITATION

References

  • Bahlis, N.J., Jordan-McMurry, I., Grad, J.M., Reis, I., Neel, J., Kharfan-Dabaja, M.A., Eckman, J., Goodman, M., Fernadez, H.F., Boise, L.H. & Lee, K.P. (2001) Phase I results from a phase I/II study of arsenic trioxide (As2O3) and ascorbic acid (AA) in relapsed and chemorefractory multiple myeloma. Blood, 98, 375a.
  • Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D. & Tricot, G. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98, 492494.
  • Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski, J. & Springer, T.A. (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature, 382, 829833.
  • Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T.A. & Anderson, K.C. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood, 87, 11041112.
  • Chauhan, D., Pandey, P., Hideshima, T., Treon, S., Raje, N., Davies, F.E., Shima, Y., Tai, Y.T., Rosen, S., Avraham, S., Kharbanda, S. & Anderson, K.C. (2000) SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. Journal of Biological Chemistry, 275, 2784527850.
  • Chauhan, D., Catley, L., Hideshima, T., Li, G., Leblanc, R., Gupta, D., Sattler, M., Richardson, P., Schlossman, R., Podar, K., Weller, E., Munshi, N. & Anderson, K.C. (2002) 2-Methoxyestradiol (2ME2) overcome drug resistance in multiple myeloma cells. Blood, 100, 21872194.
  • Chomarat, P., Banchereau, J., Davoust, J. & Palucka, A.K. (2000) IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nature Immunology, 1, 510514.
  • Clark, E.A. & Brugge, J.S. (1995) Integrins and signal transduction pathways: the road taken. Science, 268, 233239.
  • Corral, L.G., Haslett, P.A., Muller, G.W., Chen, R., Wong, L.M., Ocampo, C.J., Patterson, R.T., Stirling, D.I. & Kaplan, G. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. Journal of Immunology, 163, 380386.
  • Costes, V., Portier, M., Lu, Z.Y., Rossi, J.F., Bataille, R. & Klein, B. (1998) Interleukin 1 in multiple myeloma: producer cells and their role in the control of IL-6 production. British Journal of Haematology, 103, 11521160.
  • D'Amato, R.J., Loughnan, M.S., Flynn, E. & Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 40824085.
  • Damiano, J.S., Cress, A.E., Hazlehurst, L.A., Shtil, A.A. & Dalton, W.S. (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93, 16581667.
  • Dankbar, B., Padro, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R.M., Serve, H., Berdel, W.E. & Kienast, J. (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor–stromal cell interactions in multiple myeloma. Blood, 95, 26302636.
  • Davies, F.E., Rollinson, S.J., Rawstron, A.C., Roman, E., Richards, S., Drayson, M., Child, J.A. & Morgan, G.J. (2000) High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. Journal of Clinical Oncology, 18, 28432851.
  • Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. & Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210216.
  • Deaglio, S., Canella, D., Baj, G., Arnulfo, A., Waxman, S. & Malavasi, F. (2001) Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells. Leukemia Research, 25, 227235.
  • Fotsis, T., Zhang, Y., Pepper, M.S., Adlercreutz, H., Montesano, R., Nawroth, P.P. & Schweigerer, L. (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature, 368, 237239.
  • Gabrilovich, D.I., Chen, H.L., Girgis, K.R., Cunningham, H.T., Meny, G.M., Nadaf, S., Kavanaugh, D. & Carbone, D.P. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medicine, 2, 10961103.
  • Garrett, I.R., Durie, B.G., Nedwin, G.E., Gillespie, A., Bringman, T., Sabatini, M., Bertolini, D.R. & Mundy, G.R. (1987) Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. New England Journal of Medicine, 317, 526532.
  • Georgii-Hemming, P., Wiklund, H.J., Ljunggren, O. & Nilsson, K. (1996) Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood, 88, 22502258.
  • Grad, J.M., Bahlis, N.J., Reis, I., Oshiro, M.M., Dalton, W.S. & Boise, L.H. (2001) Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 98, 805813.
  • Gupta, D., Treon, S.P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.T., Lin, B., Lentzsch, S., Davies, F.E., Chauhan, D., Schlossman, R.L., Richardson, P., Ralph, P., Wu, L., Payvandi, F., Muller, G., Stirling, D.I. & Anderson, K.C. (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 15, 19501961.
  • Hallek, M., Bergsagel, P.L. & Anderson, K.C. (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91, 321.
  • Han, J.H., Choi, S.J., Kurihara, N., Koide, M., Oba, Y. & Roodman, G.D. (2001) Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor-κB ligand. Blood, 97, 33493353.
  • Haslett, P.A., Corral, L.G., Albert, M. & Kaplan, G. (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. Journal of Experimental Medicine, 187, 18851892.
  • Hayashi, T., Hideshima, T., Akiyama, M., Richardson, P., Schlossman, R., Chauhan, D., Munshi, N.C., Waxman, S. & Anderson, K.C. (2002) Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Molecular Cancer Therapeutics, 1, 851860.
  • Hazlehurst, L.A., Damiano, J.S., Buyuksal, I., Pledger, W.J. & Dalton, W.S. (2000) Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene, 19, 43194327.
  • Herrmann, J.L., Briones, Jr, F., Brisbay, S., Logothetis, C.J. & McDonnell, T.J. (1998) Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 17, 28892899.
  • Hideshima, T., Chauhan, D., Teoh, G., Raje, N., Treon, S.P., Tai, Y.T., Shima, Y. & Anderson, K.C. (2000a) Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clinical Cancer Research, 6, 11801189.
  • Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. & Anderson, K.C. (2000b) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 29432950.
  • Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P. & Anderson, K.C. (2001a) The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene, 20, 45194527.
  • Hideshima, T., Nakamura, N., Chauhan, D. & Anderson, K.C. (2001b) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene, 20, 59916000.
  • Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001c) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 30713076.
  • Hideshima, T., Chauhan, D., Hayashi, T., Podar, K., Akiyama, M., Gupta, D., Richardson, P., Munshi, N. & Anderson, K.C. (2002a) The biological sequelae of stromal cell-derived factor-1α in multiple myeloma. Molecular Cancer Therapeutics, 1, 539544.
  • Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., Adams, J. & Anderson, K.C. (2002b) NF-κB as a therapeutic target in multiple myeloma. Journal of Biological Chemistry, 277, 1663916647.
  • Hus, M., Dmoszynska, A., Soroka-Wojtaszko, M., Jawniak, D., Legiec, W., Ciepnuch, H., Hellmann, A., Wolska-Smolen, T., Skotnicki, A. & Manko, J. (2001) Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica, 86, 404408.
  • Hussein, M.A., Mason, J., Ravandi, F. & Rifkin, R.M. (2001) A phase II clinical study of arsenic trioxide (ATO) in patients (Pts) with relapsed or reflactory multiple myeloma (MM); a preliminary report. Blood, 98, 378a.
  • Jing, Y., Dai, J., Chalmers-Redman, R.M., Tatton, W.G. & Waxman, S. (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood, 94, 21022111.
  • Kawano, M., Yamamoto, I., Iwato, K., Tanaka, H., Asaoku, H., Tanabe, O., Ishikawa, H., Nobuyoshi, M., Ohmoto, Y. & Hirai, Y. (1989) Interleukin-1β rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood, 73, 16461649.
  • King, R.W., Deshaies, R.J., Peters, J.M. & Kirschner, M.W. (1996) How proteolysis drives the cell cycle. Science, 274, 16521659.
  • Kiuchi, N., Nakajima, K., Ichiba, M., Fukada, T., Narimatsu, M., Mizuno, K., Hibi, M. & Hirano, T. (1999) STAT3 is required for the gp130-mediated full activation of the c-myc gene. Journal of Experimental Medicine, 189, 6373.
  • LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J., Gupta, D., Richardson, P., Munshi, N. & Anderson, K.C. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62, 49965000.
  • Lentzsch, S., Rogers, M.S., LeBlanc, R., Birsner, A.E., Shah, J.H., Treston, A.M., Anderson, K.C. & D'Amato, R.J. (2002) S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Research, 62, 23002305.
  • Li, B. & Dou, Q.P. (2000) Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proceedings of the National Academy of Sciences of the United States of America, 97, 38503855.
  • Li, P., Sanz, I., O'Keefe, R.J. & Schwarz, E.M. (2000) NF-κB regulates VCAM-1 expression on fibroblast-like synoviocytes. Journal of Immunology, 164, 59905997.
  • Lichtenstein, A., Berenson, J., Norman, D., Chang, M. & Carlile, A. (1989) Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood, 74, 12661273.
  • Lin, B., Podar, K., Gupta, D., Tai, Y.T., Li, S., Weller, E., Hideshima, T., Lentzsch, S., Davies, F.E., Li, C., Weisberg, E., Schlossman, R., Richardson, P., Griffin, J.D., Wood, J., Munshi, N. & Anderson, K.C. (2002) The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Research, 62, 50195026.
  • Lopes, U.G., Erhardt, P., Yao, R. & Cooper, G.M. (1997) p53-dependent induction of apoptosis by proteasome inhibitors. Journal of Biological Chemistry, 272, 1289312896.
  • Michigami, T., Shimizu, N., Williams, P.J., Niewolna, M., Dallas, S.L., Mundy, G.R. & Yoneda, T. (2000) Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity. Blood, 96, 19531960.
  • Mitsiades, C., Mitsiades, N., Paulaki, V., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Treon, S., Munshi, N., Richardson, P. & Anderson, K.C. (2002) Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via IGF-1/ Akt signaling in human multiple myeloma cells: therapeutic implication. Oncogene, 21, 56735683.
  • Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N., Treon, S.P. & Anderson, K.C. (2002) Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood, 99, 40794086.
  • Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J.L., Arenzana-Seisdedos, F., Schwartz, O., Heard, J.M., Clark-Lewis, I., Legler, D.F., Loetscher, M., Baggiolini, M. & Moser, B. (1996) The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature, 382, 833835.
  • Ogata, A., Chauhan, D., Teoh, G., Treon, S.P., Urashima, M., Schlossman, R.L. & Anderson, K.C. (1997) Interleukin-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. Journal of Immunology, 159, 22122221.
  • Osman, K., Comenzo, R. & Rajkumar, S.V. (2001) Deep venous thrombosis and thalidomide therapy for multiple myeloma. New England Journal of Medicine, 344, 19511952.
  • Palombella, V.J., Rando, O.J., Goldberg, A.L. & Maniatis, T. (1994) The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell, 78, 773785.
  • Park, W.H., Seol, J.G., Kim, E.S., Hyun, J.M., Jung, C.W., Lee, C.C., Kim, B.K. & Lee, Y.Y. (2000) Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Research, 60, 30653071.
  • Pearse, R.N., Sordillo, E.M., Yaccoby, S., Wong, B.R., Liau, D.F., Colman, N., Michaeli, J., Epstein, J. & Choi, Y. (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 98, 1158111586.
  • Podar, K., Tai, Y.T., Davies, F.E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B.K., Gupta, D., Shima, Y., Chauhan, D., Mitsiades, C., Raje, N., Richardson, P. & Anderson, K.C. (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood, 98, 428435.
  • Puthier, D., Bataille, R. & Amiot, M. (1999a) IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. European Journal of Immunology, 29, 39453950.
  • Puthier, D., Derenne, S., Barille, S., Moreau, P., Harousseau, J.L., Bataille, R. & Amiot, M. (1999b) Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. British Journal of Haematology, 107, 392395.
  • Raje, N. & Anderson, K. (1999) Thalidomide – a revival story. New England Journal of Medicine, 341, 16061609.
  • Rajkumar, S.V., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Kyle, R.A., Gertz, M.A. & Greipp, P.R. (2000) Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clinic Proceedings, 75, 897901.
  • Rajku, S.V., Hayman, S.R., Gertz, M.A., Dispenzieri, A., Lacy, M., Grelpp, P.R., Geyer, N., Fonseca, R., Lust, J.A., Kyle, R. & Witzig, T.E. (2001) Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM). Blood, 98, 849a.
  • Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G.R., Tura, S., Baccarani, M. & Lemoli, R.M. (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood, 100, 230237.
  • Richardson, P., Schlossman, R., Weller, E., Hideshima, T., Mitsiades, C., Davies, F.E., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freedman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. (2002) Immunomodulatory derivative CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (in press).
  • Sanz-Rodriguez, F., Hidalgo, A. & Teixido, J. (2001) Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood, 97, 346351.
  • Sati, H.I., Greaves, M., Apperley, J.F., Russell, R.G. & Croucher, P.I. (1999) Expression of interleukin-1α and tumour necrosis factor-α in plasma cells from patients with multiple myeloma. British Journal of Haematology, 104, 350357.
  • Shain, K.H., Landowski, T.H. & Dalton, W.S. (2002) Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. Journal of Immunology, 168, 25442553.
  • Shen, Z.X., Chen, G.Q., Ni, J.H., Li, X.S., Xiong, S.M., Qiu, Q.Y., Zhu, J., Tang, W., Sun, G.L., Yang, K.Q., Chen, Y., Zhou, L., Fang, Z.W., Wang, Y.T., Ma, J., Zhang, P., Zhang, T.D., Chen, S.J., Chen, Z. & Wang, Z.Y. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89, 33543360.
  • Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 15651571.
  • Tosi, P., Ronconi, S., Zamagni, E., Cellini, C., Grafone, T., Cangini, D., Pileri, S.A., Baccarani, M., Tura, S. & Cavo, M. (2001) Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica, 86, 409413.
  • Tricot, G. (2000) New insights into role of microenvironment in multiple myeloma. Lancet, 355, 248250.
  • Tseng, S., Pak, G., Washenik, K., Pomeranz, M.K. & Shupack, J.L. (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. Journal of the American Academy of Dermatology, 35, 969979.
  • Tu, Y., Gardner, A. & Lichtenstein, A. (2000) The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Research, 60, 67636770.
  • Uchiyama, H., Barut, B.A., Mohrbacher, A.F., Chauhan, D. & Anderson, K.C. (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 82, 37123720.
  • Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F. & Dammacco, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology, 87, 503508.
  • Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F. & Dammacco, F. (1999) bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93, 30643073.
  • Weber, D.M., Gavino, M., Delasalle, K., Rankin, K. & Giralt, S. & Alexanian, R (1999) Thalidomide alone or with dexamethasone for multiple myeloma. Blood, 94, 604a.
  • Wood, J.M., Bold, G., Buchdunger, E., Cozens, R., Ferrari, S., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., Persohn, E., Rosel, J., Schnell, C., Stover, D., Theuer, A., Towbin, H., Wenger, F., Woods-Cook, K., Menrad, A., Siemeister, G., Schirner, M., Thierauch, K.H., Schneider, M.R., Drevs, J., Martiny-Baron, G. & Totzke, F. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Research, 60, 21782189.
  • Xu, F., Gardner, A., Tu, Y., Michl, P., Prager, D. & Lichtenstein, A. (1997) Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. British Journal of Haematology, 97, 429440.